iPoster : AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational Phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

Download PDF

Add Notes

AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational Phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer